Bendamustine in CLL: How quickly will today's consensus become tomorrow's memory?

Cheson, Bruce D.

doi:10.1016/j.leukres.2014.08.003

Cited by 4 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Italian CLL guidelines therefore recommend that elderly and comorbid patients should receive a reduced bendamustine dose of 70 mg/m 2 for up to six cycles. The minimum effective dose of bendamustine is approximately 50 mg/m 2 [Cheson, 2014, Cuneo et al 2014].…”

Section: Management Of Chronic Lymphocytic Leukaemia In Elderly or Unmentioning

confidence: 99%

Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review

Al‐Sawaf

Cramer

Goede

et al. 2017

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

Patients with a high comorbidity burden (i.e. a CIRS score higher than 6) or relevant organ impairment should receive a therapy adapted to their physical status. This includes agents like chlorambucil in combination with a CD20 antibody, that is, rituximab, obinutuzumab or ofatumumab, bendamustine, and as of late, the bruton-tyrosine kinase inhibitor ibrutinib. For patients with del17p and possibly TP53 mutations, frontline treatment should be initiated with

show abstract

Section: Management Of Chronic Lymphocytic Leukaemia In Elderly or Unmentioning

confidence: 99%

Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review

Al‐Sawaf

Cramer

Goede

et al. 2017

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

show abstract

“…Препарат продемонстрировал несомненное преимущество по сравнению с флударабином у паци-ентов с неудачами на терапии хлорамбуцилом [7]. Бла-гоприятный профиль токсических осложнений, пред-ставленный в основном умеренной миелосупрессией, тошнотой и нетяжелыми инфекциями, делает его иде-альным агентом для включения в комбинации с дру-гими препаратами.…”

Section: ' 2 0 5 введениеunclassified

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study

et al. 2015

View full text Add to dashboard Cite

“…5 Bendamustine is a bifunctional agent that combines the properties of an alkylator and a purine analogue. Although bendamustine engages cell death through both dependent and independent p53 pathways, [6][7][8] patients with 17p deletions have shown to poorly respond to BR. 9,10 In addition, signals transmitted by the microenvironment play a key role in promoting cell survival and chemoresistance of CLL cells to bendamustine.…”

Section: Introductionmentioning

confidence: 99%

Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia

Lee-Vergés

Hanna

Yazdanparast

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has been shown to be highly effective in patients with chronic lymphocytic leukemia (CLL) and is approved for CLL treatment. Unfortunately, resistance and intolerance to ibrutinib has been observed in several studies, opening the door for more specific BTK inhibitors. CC‐292 (spebrutinib) is a BTK inhibitor with increased specificity for BTK and less inhibition of other kinases. Our in vitro studies showed that CC‐292 potently inhibited B‐cell receptor signaling, activation, proliferation and chemotaxis of CLL cells. In in vivo studies using the adoptive transfer TCL1 mouse model of CLL, CC‐292 reduced tumor load and normalized tumor‐associated expansion of T cells and monocytes, while not affecting T cell function. Importantly, the combination of CC‐292 and bendamustine impaired CLL cell proliferation in vivo and enhanced the control of CLL progression. Our results demonstrate that CC‐292 is a specific BTK inhibitor with promising performance in combination with bendamustine in CLL. Further clinical trials are warranted to investigate the therapeutic efficacy of this combination regimen.

show abstract

Bendamustine in CLL: How quickly will today's consensus become tomorrow's memory?

Cited by 4 publications

References 7 publications

Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review

Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study

Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia

Contact Info

Product

Resources

About